Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation
Conclusions:
Our study identified for the first time gene promoter hypomethylation as a distinctive subtype-specific mechanism for controlling the expression of a key regulator of Rac-mediated motility and metastasis in breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 24, 2014 Category: Cancer & Oncology Authors: Laura Barrio-RealLorena BenedettiNora EngelYaping TuSoonweng ChoSaraswati SukumarMarcelo Kazanietz Source Type: research
Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation
Targeting the function of epidermal growth factor receptor (EGFR) has failed as an effective clinical option for breast cancer. Understanding the drivers of inherent resistance has been a challenge. One possible mechanism is the acquisition of stem-like properties through the process of epithelial-mesenchymal transition. A recent study by Seguin and colleagues adds to our understanding of this process by demonstrating a functional role for unligated ?v?3 integrin in mediating a stem-like phenotype and facilitating resistance to EGFR-targeted therapy via enhanced downstream coupling to a KRAS:RalB:NF-?B pathway. Importantly...
Source: Breast Cancer Research - September 23, 2014 Category: Cancer & Oncology Authors: Wells BrownMichael Wendt Source Type: research
Digital mammographic density and breast cancer risk: a case¿control study of six alternative density assessment methods
IntroductionMammographic density is a strong breast cancer risk factor and a major determinant of screening sensitivity. However, there is currently no validated estimation method for full-field digital mammography (FFDM).
Methods:
The performance of three area-based approaches (BI-RADS, the semi-automated Cumulus, and the fully-automated ImageJ-based approach) and three fully-automated volumetric methods (Volpara, Quantra and single X-ray absorptiometry (SXA)) were assessed in 3168 FFDM images from 414 cases and 685 controls. Linear regression models were used to assess associations between breast cancer risk factors and ...
Source: Breast Cancer Research - September 20, 2014 Category: Cancer & Oncology Authors: Amanda EngZoe GallantJohn ShepherdValerie McCormackJingmei LiMitch DowsettSarah VinnicombeSteve AllenIsabel dos-Santos-Silva Source Type: research
The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services
Conclusions:
The Angelina Jolie effect has been long lasting and global, and appears to have increased referrals to centres appropriately. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 19, 2014 Category: Cancer & Oncology Authors: D EvansJulian BarwellDiana EcclesAmanda CollinsLouise IzattChris JacobsAlan DonaldsonAngela BradyAndrew CuthbertRachel HarrisonSue ThomasAnthony HowellZosia MiedzybrodzkaAlex Murray Source Type: research
A novel role for ezrin in breast cancer angio/lymphangiogenesis
Conclusion:
The results describe a novel function for ezrin in the regulation of tumour-induced angio/lymphangiogenesis promoted by Src in breast cancer. The combination of Src/ezrin might prove to be a beneficial prognostic/predictive biomarker for early stage metastatic breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 18, 2014 Category: Cancer & Oncology Authors: Abdi GhaffariVictoria HoskinAlvin SzetoMaaike HumNavid LiaghatiKanji NakatsuYolanda MadarnasSandip SenGuptaBruce Elliott Source Type: research
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A dependent phospho-Akt inactivation in estrogen-receptor negative human breast cancer cells
Conclusions:
Inhibition of CIP2A determines the effects of tamoxifen-induced apoptosis in ER-negative breast cancer cells. Our data suggest a novel ?off-target? mechanism of tamoxifen and suggest that CIP2A/PP2A/p-Akt signaling as a feasible anti-cancer pathway. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 17, 2014 Category: Cancer & Oncology Authors: Chun-Yu LiuMan-Hsin HungDuen-Shian WangPei-Yi ChuJung-Chen SuTsung-Han TengChun-Teng HuangTing-Ting ChaoCheng-Yi WangChung-Wai ShiauLing-Ming TsengKuen-Feng Chen Source Type: research
miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple negative breast cancer
Conclusions:
Our findings suggest that miR-638 plays an important role in TNBC progression via BRCA1 deregulation. Therefore, miR-638 might serve as a potential prognostic indicator and therapeutic target for breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 17, 2014 Category: Cancer & Oncology Authors: Xiaohui TanJin PengYebo FuShejuan AnKatayoon RezaeiSana TabbaraChristine TealYan-gao ManRachel BremSidney Fu Source Type: research
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination
IntroductionTraditional factors currently used for prognostic stratification do not always predict adequately treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in breast cancer patients with limited metastatic dissemination.
Methods:
492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to starting a new line of system...
Source: Breast Cancer Research - September 16, 2014 Category: Cancer & Oncology Authors: Mario GiulianoAntonio GiordanoSummer JacksonUgo De GiorgiMichal MegoEvan CohenHui GaoSimone AnfossiBeverly HandyNaoto UenoRicardo AlvarezSabino De PlacidoVicente ValeroGabriel HortobagyiJames ReubenMassimo Cristofanilli Source Type: research
The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells
Conclusions:
Collectively, our findings uncover novel roles for FOXM1 and FOXM1-regulated genes in promoting cancer stem-like cell properties and therapy resistance, and highlight the relevance of FOXM1 as a therapeutic target to be considered for reducing invasiveness and enhancing breast cancer response to endocrine treatments. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 12, 2014 Category: Cancer & Oncology Authors: Anna BergamaschiZeynep Madak-ErdoganYu KimYoon-La ChoiHailing LuBenita Katzenellenbogen Source Type: research
Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
Conclusions:
Our study shows that TNBC cells have profound metabolic alterations characterized by decreased mitochondrial respiration and increased glycolysis. Due to their impaired mitochondrial function, TNBC cells are highly sensitive to glycolytic inhibition, suggesting that such metabolic intervention may be an effective therapeutic strategy for this subtype of breast cancer cells. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 11, 2014 Category: Cancer & Oncology Authors: Hélène PelicanoWan ZhangJinyun LiuNaima HammoudiJiale DaiRui-hua XuLajos PusztaiPeng Huang Source Type: research
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
Conclusions:
Moderate reduction in PTEN, without complete loss, can activate the PI3K pathway to cause endocrine resistance in ER-positive breast cancer, which can be overcome by combining endocrine therapy with inhibitors of the PI3K pathway. Our data suggests that the ER degrader fulvestrant, to block both ligand-dependent and -independent ER signaling, combined with an AKT inhibitor is an effective strategy to test in patients. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 11, 2014 Category: Cancer & Oncology Authors: Xiaoyong FuChad CreightonNrusingh BiswalVijetha KumarMartin SheaSabrina HerreraAlejandro ContrerasCarolina GutierrezTao WangSarmistha NandaMario GiulianoGladys MorrisonAgostina NardoneKristen KarlinThomas WestbrookLaura HeiserPavana AnurPaul SpellmanSylvi Source Type: research
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen ¿ urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression
Conclusions:
Our findings point out extracellular serine proteases, in particular plasmin, and uPAR as valuable therapeutic targets against ILEI-driven tumor progression and emphasize the prognostic relevance of ILEI localization and a combined ILEI-uPAR marker analysis in human breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 9, 2014 Category: Cancer & Oncology Authors: Agnes CsiszarBetül KutaySilvia WirthUlrike SchmidtSabine Macho-MaschlerMartin SchreiberMemetcan AlacakaptanGeorg VogelKarin AumayrLukas HuberHartmut Beug Source Type: research
Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signaling networks and conserved oncogenic pathways
Conclusion:
This study provides network-level insights into signaling in these breast cancer models and demonstrates that comparative phosphoproteomics can identify conserved oncogenic signaling pathways. The Met-amplified, p53-null tumours provide a new pre-clinical model for a subset of triple-negative breast cancers. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 9, 2014 Category: Cancer & Oncology Authors: Naveid AliJianmin WuFalko HochgräfeHoward ChanRadhika NairSunny YeLuxi ZhangRuth LyonsMark PineseHong LeeNicola ArmstrongChristopher OrmandySusan ClarkAlexander SwarbrickRoger Daly Source Type: research
Prognostic significance of FOXP3+ tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
Conclusions:
FOXP3+ regulatory TILs are a poor prognostic indicator in ER+ breast cancer, but a favorable prognostic factor in the HER2+/ER? subtype. The prognostic value of FOXP3+ TILs in breast cancer differs depending on ER and HER2 expression status and CD8+ T-cell infiltration. (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 6, 2014 Category: Cancer & Oncology Authors: Shuzhen LiuWilliam FoulkesSamuel LeungDongxia GaoSherman LauZuzana KosTorsten Nielsen Source Type: research
Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
Conclusions:
Four weeks of neoadjuvant lapatinib in patients with HER2-positive DCIS resulted in inhibition of HER2 and RAS/MAPK signaling pathway.Trial registration: 2008-004492-21 (Registered June 25th 2008). (Source: Breast Cancer Research)
Source: Breast Cancer Research - September 4, 2014 Category: Cancer & Oncology Authors: Laura EstévezAna Suarez-GauthierElena GarcíaCristina MiróIsabel CalvoMaría Fernández-AbadMercedes HerreroManuel MarcosCristina MárquezFernando Lopez RíosSofía PereaManuel Hidalgo Source Type: research
